SMYD5

Across TCGA pan-cancer cohorts, SMYD5 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated SMYD5 data layer compared with 2 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SMYD5 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated SMYD5 expression acts as an unfavorable survival marker, although some lineages such as BRCA and UVM show a favorable association.

LIHC, ACC, and KICH are the cancer types where SMYD5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.601	0.760	<.001	97	view →
ACC	DFS	Median	All	0.387	0.765	<.001	80	view →
KICH	DFS	Median	All	0.660	1.000	.003	41	view →
BLCA	DFS	Tertile	All	0.148	0.506	<.001	38	view →
UCEC	DFS	Tertile	All	0.792	0.885	.004	28	view →
BRCA	OS	Quartile	III,IV	0.958	0.842	.004	24	view →
COAD	DFS	Median	II,III,IV	0.390	0.562	.006	21	view →
PAAD	DFS	Quartile	All	0.399	0.729	.004	19	view →
UVM	OS	Median	All	0.933	0.769	.017	18	view →
CESC	DFS	Median	II,III,IV	0.703	0.861	.016	16	view →
LUSC	OS	Median	III,IV	0.463	0.688	.011	15	view →
HNSC	DFS	Quartile	All	0.492	0.628	.020	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

SMYD5–LIHC (OS)

Open the LIHC breakdown →